RETpositive

Research, news and advocacy for caregivers and patients impacted by RET-driven cancers. Research is hope!🧬🔬

[RETpositive @RETpositive]

Chad, Sarah, Brittany& Linda are all never-smokers with RET-positive #lungcancer. They are parents, siblings, friends & spouses. This is their story. #lcsm @StephenVLiu @NarjustFlorezMD @VivekSubbiah https://t.co/yK80vu7sRZ

[RETpositive @RETpositive]

Proud to announce our collaboration with @23andme + 19 lung cancer advocacy groups to advance the Lung Cancer Genetics Study. US #lungcancer survivors: pls join & help us drive life-saving scientific discoveries. #lcsm

https://t.co/CAcQMh9BZ1

[Journal of Clinical Oncology @JCO_ASCO]

‼️ #ASCO24 simultaneous publication by Williams et al:

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced #NSCLC: https://t.co/iTbarTBilu

[Lilly Oncology Medical @LillyOncMed]

#ASCO24 Rapid Oral Presentation: Safety and efficacy of a selective RET inhibitor in pediatric and adolescent patients with RET-altered solid tumors.

Results from the phase 1/2 LIBRETTO-121 study: https://t.co/Qsh6kB9k6E

#CancerResearch #PrecisionMedicine

[Lilly Oncology Medical @LillyOncMed]

At #ASCO24, see our poster presentation examining a selective RET inhibitor in patients with non-MTC RET-mutated tumors.

Results from the LIBRETTO-001 study: https://t.co/qrA4Iu421j

#CancerResearch #PrecisionMedicine

[Lilly Oncology Medical @LillyOncMed]

At #ASCO24, we’re sharing intracranial outcomes data from LIBRETTO-431, a phase 3 study investigating front-line use of a selective RET inhibitor in patients with RET fusion+ advanced #NSCLC.

Read the results here: https://t.co/U9suO5brbK

#CancerResearch #LungCancer #LCSM

[RETpositive @RETpositive]

Very important questions regarding management of other oncogene addicted nsclc in light of this data!

[Stephen V Liu, MD @StephenVLiu]

Dr. @LeciaSequist with a brilliant #ASCO24 discussion of LAURA and #EGFR NSCLC. Do we apply this paradigm now to subtypes with CNS active agents that have long term safety data like #ALK and #RET? I think so!

[Prof Tom John @TommyJohn00]

Excellent discussion from @LeciaSequist We can’t do the same for all oncogene driven tumours. Worth considering if there is CNS penetration and low tox. Access will be issue. #LCSM #ASCO24

[LUNGevity Foundation @LUNGevity]

Our latest blog features @TejasPatilMD as he highlights the importance of teamwork in #lungcancerresearch and why his work to study #MET & #EGFR signaling pathways may help us overcome drug resistance in multiple types of lung cancer. https://t.co/Xr8fouruBL #RET #lcsm

[D. Ross Camidge @DRCamidge]

Every year since 2018 we have gathered 5 or more year survivors of lung cancer together at CU to show others that hope has a face. This is the May 11th 2024 gathering. Rock on!

[RETpositive @RETpositive]

@ros1cancer @ALKPositiveinc @EGFRResisters @ALKpositiveINT @TejasPatilMD @metcrusaders @RetRenegades @OncogeneCancer #lcsm

[RETpositive @RETpositive]

Targeting EGFR and MET pathways to overcome resistance to targeted therapies. Thanks to the Hamoui Foundation, Lungevity, Dr. Patil and partners for this exciting research-- potentially relevant for multiple drivers!

https://t.co/nUNEv4hq26

[EGFR Resisters @EGFRResisters]

Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review

https://t.co/f9DLjCPelY

[RETpositive @RETpositive]

Thank you Dr. Watanabe, Lungevity and the patient community who helped fund this important research. #patientadvocacy #lcsm @LUNGevity

[LUNGevity Foundation @LUNGevity]

In our latest blog, Dr. Hideo Watanabe (@IcahnMountSinai) shares updates on what is happening in his lab that could improve the long-term effectiveness of targeted therapy treatment for #lungcancer patients. Read here: https://t.co/wQxULE2XtB @RETpositive

[LUNGevity Foundation @LUNGevity]

In our latest blog, Dr. Hideo Watanabe (@IcahnMountSinai) shares updates on what is happening in his lab that could improve the long-term effectiveness of targeted therapy treatment for #lungcancer patients. Read here: https://t.co/wQxULE2XtB @RETpositive

[RETpositive @RETpositive]

Great news!
https://t.co/uka9Le8iO2

[Ben Westphalen @BenWestphalen]

Big news for European #cancer #patients 🇪🇺

Selpercatinib has been approved by @EMA_News for advanced RET fusion positive solid tumours 🎯

This marks the 2nd tumour agnostic, biomarker-driven approval in the EU.

#PrecisionMedicine @OncoAlert 🚨

https://t.co/kYe2kTTrV6

[FlorezLab @Florez_Lab]

📌Did You Know?

📌The FIRST International Pregnancy and Lung Cancer Registry has been created by the #FlorezLab, to understand the disease in this special population.

📌Anyone, ANYWHERE in the world can enter their own cases

Email us📩: [email protected]

[Erin Schenk, MD, PhD @SchenkLab]

Don’t miss out! My colleague @TejasPatilMD presenting his exciting work on early MET bypass signaling in ALK and RET driven NSCLC. He is also an @CUCancerCenter Rising Star! @LUNGevity @ALKPositiveinc @RETpositive #LCSM #AACR24

[RETpositive @RETpositive]

Brittany, a young Mom & never-smoker, was diagnosed w/ #RET+ #lungcancer at 36. #IAmRETPositive #lcsm https://t.co/7KytGMupGj